PRODUCT INFORMATION



BPIQ-I

Item No. 17224

CAS Registry No.: 174709-30-9

Formal Name: N-(3-bromophenyl)-3-methyl-3H-

imidazo[4,5-g]quinazolin-8-amine

Synonym: PD 159121 MF: C₁₆H₁₂BrN₅ 354.2 FW: **Purity:** ≥95%

 λ_{max} : 240, 265, 351, 366 nm UV/Vis.:

Supplied as: A crystalline solid

Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



BPIQ-I is supplied as a crystalline solid. A stock solution may be made by dissolving the BPIQ-I in the solvent of choice, which should be purged with an inert gas. BPIQ-I is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of BPIQ-I in these solvents is approximately 30 and 20 mg/ml, respectively.

BPIQ-I is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BPIQ-I should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. BPIQ-I has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

BPIQ-I is a quinazoline that inhibits the tyrosine kinase activity of the epidermal growth factor receptor (IC $_{50}$ = 0.025 nM).¹ It can inhibit the growth of SKOV3 and MDA-468 tumor cell lines with EC_{50} values of 6.5 and 30 μ M, respectively.²

References

- 1. Rewcastle, G.W., Palmer, B.D., Bridges, A.J., et al. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 39(4), 918-928 (1996).
- 2. Rae, J.M. and Lippman, M.E. Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors. Breast Cancer Res. Treat. 83(2), 99-107 (2004).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 11/14/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM